A Life-Changing Discovery
Myriad Genetics ($MYGN) has partnered with actress and Netflix star Jackie Tohn to amplify awareness surrounding hereditary cancer testing, following her personal discovery of a BRCA1 gene variant that fundamentally altered her health trajectory. Tohn's story—uncovering an 85% lifetime risk of breast cancer and a 65% risk of ovarian cancer through genetic screening—underscores how early detection through advanced testing can enable preventive interventions that potentially save lives. Her public decision to share this deeply personal health challenge with millions represents a significant momentum-building moment for the hereditary cancer testing sector and Myriad's portfolio of diagnostic solutions.
The partnership centers on promoting MyRisk® Hereditary Cancer Test, a comprehensive genomic screening tool that evaluates 63 genes across 11 different cancer types. This breadth of analysis distinguishes MyRisk from narrower genetic tests that focus solely on BRCA mutations, making it a more inclusive screening option for individuals concerned about hereditary cancer predisposition. Tohn's case exemplifies the test's clinical value: her positive BRCA1 result enabled her to make informed decisions about preventive measures before any cancer diagnosis emerged—a textbook example of precision medicine preventing disease rather than merely treating it.
The Evolving Landscape of Hereditary Cancer Testing
The hereditary cancer diagnostics market has experienced explosive growth over the past decade as genomic sequencing costs have declined and clinical evidence supporting preventive interventions has strengthened. Myriad Genetics maintains a dominant position in this space, but faces growing competition from players including Invitae ($NVTA), which offers similar multi-gene hereditary cancer panels, and specialized oncology-focused genomics firms.
Key market dynamics shaping this sector include:
- Increased insurance coverage: Major insurers now cover hereditary cancer testing for qualifying patients, expanding addressable market
- Direct-to-consumer awareness: Celebrity partnerships and public health campaigns have normalized genetic testing conversations
- Precision medicine integration: Oncologists increasingly recommend pre-symptomatic testing as standard care for high-risk populations
- Preventive care shift: Healthcare systems are investing in prevention protocols, creating demand for upfront genetic screening
MyRisk's accessibility through both traditional healthcare providers and virtual care platforms reflects the industry's digital transformation. This omnichannel approach removes friction from the testing process—a critical factor given that many individuals unaware of their hereditary cancer risk may never seek testing without convenient access pathways.
Market Implications and Investor Considerations
Myriad's partnership with Tohn arrives at a strategic moment for the company. The hereditary cancer testing market is projected to expand significantly as:
- Awareness campaigns reduce stigma and knowledge gaps about genetic predisposition
- More individuals undergo testing, creating a larger patient database for Myriad's precision medicine initiatives
- Preventive surgeries and medication protocols (like prophylactic mastectomies and tamoxifen therapy) become more common, potentially driving downstream revenue in surgical and pharmaceutical segments
Tohn's documented 85% breast cancer risk and decision to pursue preventive measures illustrates why investors should track the impact of public figures on hereditary testing adoption rates. Celebrity health disclosures have historically moved consumer behavior—think of Angelina Jolie's 2013 announcement of her BRCA1 status, which triggered what analysts termed the "Jolie Effect," substantially increasing genetic testing volumes.
For $MYGN shareholders, this partnership represents a low-cost awareness initiative with potentially outsized returns. Expanding the MyRisk customer base doesn't require significant new capital expenditure; instead, it leverages existing laboratory infrastructure and genetic counseling capabilities. Higher testing volumes directly improve gross margins and support the company's path to profitability and cash generation.
The competitive landscape remains competitive, however. Invitae has aggressively pursued market share through insurance reimbursement optimization and expanded testing panels, while newer entrants continue fragmenting the space. Myriad must maintain clinical evidence superiority and provider relationships to defend its market position.
Looking Forward: Prevention as Profit Driver
Tohn's story encapsulates a broader healthcare transformation—the shift from reactive disease management to proactive prevention. An 85% lifetime breast cancer risk is staggering, yet entirely actionable through current medical interventions. This paradox creates powerful incentives for individuals to seek genetic testing, providing tailwinds for Myriad Genetics and the hereditary cancer diagnostics sector.
As more high-profile individuals share their genetic testing journeys, the stigma surrounding hereditary cancer predisposition continues eroding. Healthcare systems simultaneously recognize that preventing cancer through early identification and preventive measures delivers superior outcomes and lower long-term costs compared to treating advanced cancers. These macro trends position hereditary cancer testing as a secular growth industry for at least the next decade, with Myriad positioned as the sector's established leader despite intensifying competition.
The real measure of this partnership's success won't appear in next quarter's earnings—it will emerge gradually as awareness spreads and testing adoption accelerates among individuals who otherwise might never discover their genetic risk until disease strikes.